RxDoctor Payments Data

Khaled Saleh, MD

Cardiovascular Disease · Corbin, KYNPI 1689767543

Payments from drug & device makers

$3,940in general payments, 2019–2025

Across 241 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$688
  • Merck$506
  • Johnson & Johnson$251
  • Abbott$200
  • AstraZeneca$141
  • plus $881 from 16 others

What the payments were for

  • Food & beverage$3,82897%
  • Education$1133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,940 in reported general payments places this provider in the 55th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$142,015
Medicare patients
1,098
Services billed
2,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$249,311
EntrestoSacubitril/Valsartan92$125,986
XareltoRivaroxaban75$83,542
JardianceEmpagliflozin40$49,861
Repatha SureclickEvolocumab51$47,117
LeqvioInclisiran Sodium13$42,556
FarxigaDapagliflozin Propanediol26$33,628
VascepaIcosapent Ethyl50$26,205
Ranolazine ErRanolazine55$13,408
BrilintaTicagrelor19$12,108
Praluent PenAlirocumab11$11,207
Rosuvastatin Calcium558$4,750
Metoprolol Succinate387$4,158
Icosapent Ethyl11$3,714
Digoxin31$3,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$688$249,311281 claims
NovartisEntresto, Leqvio$1,274$168,542105 claims
Johnson & JohnsonXarelto$251$83,54275 claims
Boehringer IngelheimJardiance$114$49,86140 claims
AstraZenecaFarxiga, Brilinta$141$45,73645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →